|
1
|
van Hagen P, Hulshof MC, van Lanschot JJ,
et al: Preoperative chemoradiotherapy for esophageal or junctional
cancer. N Engl J Med. 366:2074–2084. 2012.
|
|
2
|
Tomblyn MB, Goldman BH, Thomas CR Jr, et
al: Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy
as definitive treatment for locally advanced, unresectable
esophageal cancer: a phase-II study of the SWOG (S0414). J Thorac
Oncol. 7:906–912. 2012. View Article : Google Scholar
|
|
3
|
Murtaza M, Dawson SJ, Tsui DW, et al:
Non-invasive analysis of acquired resistance to cancer therapy by
sequencing of plasma DNA. Nature. 497:108–112. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gao D, Hu J, Zhang X, Gao C and Hong J:
Effect of hOGG1 over-expression on cisplatin resistance in
esophageal squamous carcinoma cells. Cancer Biother Radiopharm.
28:433–440. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Khedgikar V, Kushwaha P, Gautam J, et al:
Withaferin A: a proteasomal inhibitor promotes healing after injury
and exerts anabolic effect on osteoporotic bone. Cell Death Dis.
4:e7782013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li X, Huang T, Jiang G, Gong W, Qian H and
Zou C: Proteasome inhibitor MG132 enhances TRAIL-induced apoptosis
and inhibits invasion of human osteosarcoma OS732 cells. Biochem
Biophys Res Commun. 439:179–186. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stoll SJ, Pitt SC and Chen H: Follicular
thyroid cancer cell growth inhibition by proteosome inhibitor
MG132. J Surg Res. 156:39–44. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Duraj J, Pastorek M, Vitkovska J, et al:
Proteasome inhibition leads to altered signaling in the proteome of
cisplatin-resistant human ovarian carcinoma cell line. Neoplasma.
60:627–634. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fribley AM, Evenchik B, Zeng Q, et al:
Proteasome inhibitor PS-341 induces apoptosis in
cisplatin-resistant squamous cell carcinoma cells by induction of
Noxa. J Biol Chem. 281:31440–31447. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fribley A, Zeng Q and Wang CY: Proteasome
inhibitor PS-341 induces apoptosis through induction of endoplasmic
reticulum stress-reactive oxygen species in head and neck squamous
cell carcinoma cells. Mol Cell Biol. 24:9695–9704. 2004. View Article : Google Scholar
|
|
11
|
He YF, Ji CS, Hu B, et al: A phase II
study of paclitaxel and nedaplatin as front-line chemotherapy in
Chinese patients with metastatic esophageal squamous cell
carcinoma. World J Gastroenterol. 19:5910–5916. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kurosu T, Nagao T, Wu N, Oshikawa G and
Miura O: Inhibition of the PI3K/Akt/GSK3 pathway downstream of
BCR/ABL, Jak2-V617F, or FLT3-ITD downregulates DNA damage-induced
Chk1 activation as well as G2/M arrest and prominently enhances
induction of apoptosis. PLoS One. 8:e794782013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen WW, Lin CC, Huang TC, Cheng AL, Yeh
KH and Hsu CH: Prognostic factors of metastatic or recurrent
esophageal squamous cell carcinoma in patients receiving three-drug
combination chemotherapy. Anticancer Res. 33:4123–4128.
2013.PubMed/NCBI
|
|
14
|
Shi Y, Qin R, Wang ZK and Dai GH:
Nanoparticle albumin-bound paclitaxel combined with cisplatin as
the first-line treatment for metastatic esophageal squamous cell
carcinoma. Onco Targets Ther. 6:585–591. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tu Y, Chen C, Pan J, Xu J, Zhou ZG and
Wang CY: The Ubiquitin Proteasome Pathway (UPP) in the regulation
of cell cycle control and DNA damage repair and its implication in
tumorigenesis. Int J Clin Exp Pathol. 5:726–738. 2012.PubMed/NCBI
|
|
16
|
Yang H, Landis-Piwowar K, Chan TH and Dou
QP: Green tea polyphenols as proteasome inhibitors: implication in
chemoprevention. Curr Cancer Drug Targets. 11:296–306. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kandilis AN, Karidis NP, Kouraklis G,
Patsouris E, Vasileiou I and Theocharis S: Proteasome inhibitors:
possible novel therapeutic strategy for ischemia-reperfusion
injury? Expert Opin Investig Drugs. 23:67–80. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Flemming A: Therapeutics: opening the door
to a new class of proteasome inhibitors. Nat Rev Cancer. 12:52011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen FZ and Zhao XK: Ubiquitin-proteasome
pathway and prostate cancer. Onkologie. 36:592–596. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gu JJ, Hernandez-Ilizaliturri FJ, Kaufman
GP, et al: The novel proteasome inhibitor carfilzomib induces cell
cycle arrest, apoptosis and potentiates the anti-tumour activity of
chemotherapy in rituximab-resistant lymphoma. Br J Haematol.
162:657–669. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hui B, Shi YH, Ding ZB, et al: Proteasome
inhibitor interacts synergistically with autophagy inhibitor to
suppress proliferation and induce apoptosis in hepatocellular
carcinoma. Cancer. 118:5560–5571. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Altmann A, Markert A, Askoxylakis V, et
al: Antitumor effects of proteasome inhibition in anaplastic
thyroid carcinoma. J Nucl Med. 53:1764–1771. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rastogi N and Mishra DP: Therapeutic
targeting of cancer cell cycle using proteasome inhibitors. Cell
Div. 7:262012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
da Cunha FM, Demasi M and Kowaltowski AJ:
Aging and calorie restriction modulate yeast redox state, oxidized
protein removal, and the ubiquitin-proteasome system. Free Radic
Biol Med. 51:664–670. 2011.PubMed/NCBI
|
|
25
|
Chitra S, Nalini G and Rajasekhar G: The
ubiquitin proteasome system and efficacy of proteasome inhibitors
in diseases. Int J Rheum Dis. 15:249–260. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
de Almagro MC and Vucic D: The inhibitor
of apoptosis (IAP) proteins are critical regulators of signaling
pathways and targets for anti-cancer therapy. Exp Oncol.
34:200–211. 2012.PubMed/NCBI
|
|
27
|
Napetschnig J and Wu H: Molecular basis of
NF-κB signaling. Annu Rev Biophys. 42:443–468. 2013.
|
